0A6I.LSE Soligenix, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 0A6I.LSE undervalued?

Graham number

The Graham number of Soligenix, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Soligenix, Inc. fundamental analysis

No fundamental analysis for Soligenix, Inc. yet.

Soligenix, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Soligenix, Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulato…

Full company profile